PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMOGlobeNewsWire • 10/23/23
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerGlobeNewsWire • 10/11/23
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)GlobeNewsWire • 10/03/23
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)GlobeNewsWire • 10/02/23
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101GlobeNewsWire • 09/25/23
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical StudiesGlobeNewsWire • 09/20/23
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023GlobeNewsWire • 09/13/23
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/23
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 TrialGlobeNewsWire • 08/14/23
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/07/23
PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301GlobeNewsWire • 07/11/23
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/30/23
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023GlobeNewsWire • 06/20/23
PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment ProspectsSeeking Alpha • 05/27/23